Heart Failure | Current Treatment | Detailed, Expanded Analysis: Chronic Heart Failure - Treatment Algorithms: Claims Data Analysis (US)

Publish date: April 2019

Login to access report

First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a second- or third-line treatment is often needed to better manage the disease. The CHF market is heavily genericized, and prescribers have many drugs and drug classes from which to call upon, creating a high barrier to uptake for novel branded agents. This CHF treatment algorithm offers insight into the prescribing patterns across all CHF patients in the United States.


  •  What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CHF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CHF patients? ·
  • How has Entresto been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of CHF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  •  What percentage of CHF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations? · What are the product-level compliance and persistency rates among drug-treated patients


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Chronic Heart Failure - Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms: Claims Data Analysis | Chronic Heart Failure | US | May 2019

Author(s): Dwaipayan Chatterjee, M.Pharm

Dwaipayan Chatterjee is an Analyst in the Cardiovascular, Metabolism Renal and Hematology disease team at Decision Resources Group. He holds a degree with specialization in Pharmaceutical Chemistry from Birla Institute of Technology & Science, Pilani, Rajasthan, India. Prior joining DRG, he worked as an Equity Analyst for the Healthcare sector with Market Realist working on competitive intelligence and analysis of pharmaceutical financial data. He also worked as a market research analyst for Mordor Intelligence with experience of market sizing, forecasting, and analyzing market dynamics.